The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Hull Hans since 2015.
This trader's CIK number is 1614876.
At the time of last reporting, Hull Hans was the Chief Business Officer of Pliant Therapeutics, Inc.. (stock ticker symbol PLRX).
Also see all insider trading activities at Pliant Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2015 | AAVL | 0 | $0 | 34,500 | $1,297,294 | 42,800 | $8,132 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | PLRX | 0 | $0 | 15,936 | $178,499 | 0 | $0 |
| 2024 | PLRX | 0 | $0 | 19,686 | $283,056 | 0 | $0 |
| 2023 | PLRX | 0 | $0 | 61,892 | $1,261,250 | 10,591 | $22,029 |
| 2022 | PLRX | 0 | $0 | 8,748 | $167,104 | 0 | $0 |
| 2021 | PLRX | 0 | $0 | 0 | $0 | 8,000 | $16,640 |
1. Adverum Biotechnologies, Inc. (AAVL)
2. Pliant Therapeutics, Inc. (PLRX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2015-06-12 | AAVL | Option Ex | 8,300 | .19 | 1,577 |
| 2015-06-04 | [AAVL] | Option Ex | 2,000 | .19 | 380 |
| 2015-06-04 | [AAVL] | Sale | 2,000 | 37.64 | 75,284 |
| 2015-05-04 | AAVL | Sale | 5,000 | 30.87 | 154,350 |
| 2015-05-04 | AAVL | Option Ex | 5,000 | .19 | 950 |
| 2015-04-07 | AAVL | Sale | 27,500 | 38.82 | 1,067,660 |
| 2015-04-07 | AAVL | Option Ex | 27,500 | .19 | 5,225 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-17 | PLRX | Sale | 15,936 | 11.20 | 178,499 |
| 2024-07-10 | PLRX | Sale | 9,900 | 11.56 | 114,444 |
| 2024-01-17 | PLRX | Sale | 9,786 | 17.23 | 168,612 |
| 2023-08-03 | PLRX | Option Ex | 1,800 | 2.08 | 3,744 |
| 2023-08-04 | PLRX | Option Ex | 8,791 | 2.08 | 18,285 |
| 2023-08-03 | PLRX | Sale | 14,869 | 20.00 | 297,380 |
| 2023-08-04 | PLRX | Sale | 20,050 | 20.01 | 401,200 |
| 2023-07-17 | PLRX | Sale | 17,937 | 18.01 | 323,027 |
| 2023-03-30 | PLRX | Sale | 9,036 | 26.52 | 239,643 |
| 2022-12-20 | PLRX | Sale | 8,748 | 19.10 | 167,104 |
| 2021-05-26 | PLRX | Option Ex | 4,500 | 2.08 | 9,360 |
| 2020-12-30 | PLRX | Option Ex | 3,500 | 2.08 | 7,280 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hull Hans (Chief Business Officer of Pliant Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.